Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics

This study has been terminated.
(Safety concerns regarding the concomitant use of aliskiren with an ACEi or ARB.)
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Pam Marcovitz, MD, William Beaumont Hospitals Identifier:
First received: October 12, 2009
Last updated: August 2, 2016
Last verified: July 2012
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: No date given
  Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)